Creative Medical Technology (NASDAQ:CELZ) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Creative Medical Technology (NASDAQ:CELZ) to a sell rating in a report published on Saturday morning.

A number of other brokerages have also recently issued reports on CELZ. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a report on Thursday. Weiss Ratings raised Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Creative Medical Technology currently has an average rating of “Hold”.

Creative Medical Technology Trading Up 2.3%

Shares of CELZ stock opened at $1.31 on Friday. Creative Medical Technology has a 12 month low of $0.62 and a 12 month high of $6.25. The company has a market capitalization of $8.63 million, a P/E ratio of -0.63 and a beta of 1.94. The stock has a 50 day moving average of $1.20 and a two-hundred day moving average of $1.77.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Sell-side analysts predict that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CELZ. Jane Street Group LLC acquired a new position in Creative Medical Technology during the 4th quarter worth about $59,000. Clear Harbor Asset Management LLC acquired a new stake in Creative Medical Technology in the 2nd quarter valued at about $192,000. Finally, Seros Financial LLC acquired a new stake in Creative Medical Technology in the 2nd quarter valued at about $53,000. 1.42% of the stock is owned by institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.